Biologic Drugs With Established Pharmaceutical Class: Integrin Receptor Antagonist
✉ Email this page to a colleague
Biologic Drugs With Established Pharmaceutical Class: Integrin Receptor Antagonist
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 2004-11-23 | ⤷ Start Trial | ⤷ Start Trial |
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 2004-11-23 | 5,168,062 | ⤷ Start Trial |
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 2004-11-23 | 5,385,839 | ⤷ Start Trial |
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 2004-11-23 | 5,730,978 | ⤷ Start Trial |
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 2004-11-23 | 5,840,299 | ⤷ Start Trial |
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 2004-11-23 | 6,033,665 | ⤷ Start Trial |
| Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 2004-11-23 | 6,602,503 | ⤷ Start Trial |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
